Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 May;37(5):1924-1937.
doi: 10.1002/ptr.7710. Epub 2022 Dec 30.

Cannabidiol-rich non-psychotropic Cannabis sativa L. oils attenuate peripheral neuropathy symptoms by regulation of CB2-mediated microglial neuroinflammation

Vittoria Borgonetti  1 , Lisa Anceschi  2   3 , Virginia Brighenti  2 , Lorenzo Corsi  2 , Paolo Governa  4 , Fabrizio Manetti  4 , Federica Pellati  2 , Nicoletta Galeotti  1
Affiliations

Cannabidiol-rich non-psychotropic Cannabis sativa L. oils attenuate peripheral neuropathy symptoms by regulation of CB2-mediated microglial neuroinflammation

Vittoria Borgonetti et al. Phytother Res. 2023 May.

Abstract

Neuropathic pain (NP) is a chronic disease that affects the normal quality of life of patients. To date, the therapies available are only symptomatic and they are unable to reduce the progression of the disease. Many studies reported the efficacy of Cannabis sativa L. (C. sativa) on NP, but no Δ9 -tetrahydrocannabinol (Δ9 -THC)-free extracts have been investigated in detail for this activity so far. The principal aim of this work is to investigate the potential pain-relieving effect of innovative cannabidiol-rich non-psychotropic C. sativa oils, with a high content of terpenes (K2), compared to the same extract devoid of terpenes (K1). Oral administration of K2 (25 mg kg-1 ) induced a rapid and long-lasting relief of pain hypersensitivity in a mice model of peripheral neuropathy. In spinal cord samples, K2 reduced mitogen-activated protein kinase (MAPKs) levels and neuroinflammatory factors. These effects were reverted by the administration of a CB2 antagonist (AM630), but not by a CB1 antagonist (AM251). Conversely, K1 showed a lower efficacy in the absence of CB1/CB2-mediated mechanisms. In LPS-stimulated murine microglial cells (BV2), K2 reduced microglia pro-inflammatory phenotype through the downregulation of histone deacetylase 1 (HDAC-1) and nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor (IKBα) and increased interleukin-10 (IL-10) expression, an important antiinflammatory cytokine. In conclusion, these results suggested that K2 oral administration attenuated NP symptoms by reducing spinal neuroinflammation and underline the important role of the synergism between cannabinoids and terpenes.

Keywords: CB2 receptor; Cannabis sativa L.; cannabidiol; microglia; neuroinflammation; neuropathic pain.

PubMed Disclaimer

References

REFERENCES

    1. An, D., Peigneur, S., Hendrickx, L. A., & Tytgat, J. (2020). Targeting cannabinoid receptors: Current status and prospects of natural products. International Journal of Molecular Sciences, 21(14), 5064. https://doi.org/10.3390/ijms21145064
    1. Appendino, G., Chianese, G., & Taglialatela-Scafati, O. (2011). Cannabinoids: Occurrence and medicinal chemistry. Current Medicinal Chemistry, 18, 1085-1099.
    1. Atalay, S., Jarocka-Karpowicz, I., & Skrzydlewska, E. (2019). Antioxidative and anti-inflammatory properties of cannabidiol. Antioxidants (Basel, Switzerland), 9(1), 21. https://doi.org/10.3390/antiox9010021
    1. Bandyopadhaya, A., Tsurumi, A., & Rahme, L. G. (2017). NF-κBp50 and HDAC1 interaction is implicated in the host tolerance to infection mediated by the bacterial quorum sensing signal 2-aminoacetophenone. Frontiers in Microbiology, 8, 1211. https://doi.org/10.3389/fmicb.2017.01211
    1. Ben-Shabat, S., Fride, E., Sheskin, T., Tamiri, T., Rhee, M.-H., Vogel, Z., … Mechoulam, R. (1998). An entourage effect: Inactive endogenous fatty acid glycerol esters enhance 2-arachidonoyl-glycerol cannabinoid activity. European Journal of Pharmacology, 353(1), 23-31. https://doi.org/10.1016/S0014-2999(98)00392-6

LinkOut - more resources